Clinical trials: Atopic Skin
Atopic Dermatitis
A Study of ATI-502 Topical Solution for the Treatment of Atopic Dermatitis
This is an open label, multicenter study designed to evaluate the safety and tolerability of ATI-502 Topical Solution in male and female subjects with moderate or severe atopic dermatitis (AD).
- Trial name
- NCT03585296
- Testing
- ATI-502
- Where
- 6 sites in United States
- Volunteers
- 22 people
- Sponsor
- Aclaris Therapeutics, Inc.
Healthy Volunteers
Study to Access the Relative Bioavailability of Subcutaneous Dose of Nemolizumab When Administered Via Auto-Injector Versus Dual-Chamber Syringe
This study was to compare the rate and extent of absorption of a single dose of nemolizumab administered with auto-injectors [AI] (test) versus dual-chamber syringes [DCS] (reference) under controlled conditions in healthy adult…
- Trial name
- NCT05405985
- Testing
- Nemolizumab
- Where
- 2 sites in United States
- Volunteers
- 192 people, healthy volunteers welcome
- Sponsor
- Galderma R&D
Atopic Dermatitis
A Trial to Evaluate the Efficacy and Safety of Different Doses of LEO 138559 in Adults With Moderate-to-severe Atopic Dermatitis
The purpose of this trial is to test different doses of the trial medicine (LEO 138559) and see how well they work and how safe they are at treating moderate to severe atopic dermatitis in adults.
- Trial name
- NCT05923099
- Testing
- LEO 138559
- Where
- 73 sites in United States, Canada and 9 more
- Volunteers
- 262 people
- Sponsor
- LEO Pharma
Atopic Dermatitis
Effect of OC000459 on Moderate to Severe Atopic Dermatitis
The purpose of this study is to determine whether OC000459 is in reducing disease severity and preventing flares in people with moderate to severe atopic dermatitis (AD).
- Trial name
- NCT02002208
- Testing
- OC000459
- Where
- United Kingdom
- Volunteers
- 142 people
- Sponsor
- Atopix Therapeutics, Ltd.
Atopic Dermatitis
A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)
The primary objective of this study is to describe the safety and tolerability of rocatinlimab in adolescents with moderate-to-severe AD.
- Trial name
- ROCKET-Orbit (NCT05633355)
- Testing
- Rocatinlimab
- Where
- 77 sites in United States, Argentina and 7 more
- Volunteers
- 187 people
- Sponsor
- Amgen
Atopic Dermatitis
Immune Response to Yellow Fever Vaccination in Adults With Atopic Dermatitis
The main objective of the Atopic Dermatitis and Vaccinia Immunization Network (ADVN) is to reduce the risk of the fatal reaction, eczema vaccinatum (EV), to the smallpox vaccination in those with atopic dermatitis (AD).
- Trial name
- NCT00723489
- Testing
- Live Yellow Fever Vaccine (YFV-17D)
- Where
- 3 sites in United States
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Atopic Dermatitis
Cutivate Lotion HPA Axis Pediatric Study
A multi-center, open-label, Phase IV, unblinded study using Cutivate (fluticasone propionate, 0.05%)lotion and it's possible effects on the HPA axis of infants diagnosed with atopic dermatitis.
- Trial name
- NCT00546000
- Testing
- Fluticasone propionate 0.05% lotion
- Where
- 10 sites in United States
- Volunteers
- 56 people
- Sponsor
- Fougera Pharmaceuticals Inc.
Atopic Dermatitis Eczema, Atopic Dermatitis
Team-Based Connected Health (TCH) to Improve Clinical Outcomes and Access in Atopic Dermatitis
This is a pragmatic, randomized, controlled, equivalency trial. This 12-month trial will evaluate the impact of an online, team-based connected health (TCH) model for management of atopic dermatitis (AD) as compared to in-person…
- Conditions
- Atopic Dermatitis Eczema, Atopic Dermatitis, Eczema
- Trial name
- TCH in AD (NCT03981926)
- Testing
- Team-Based Connected Health (TCH)
- Where
- 2 sites in United States
- Volunteers
- 300 people
- Sponsor
- University of Southern California
Atopic Dermatitis
A Study to Determine the Safety and Tolerability of Dupilumab (REGN668/SAR231893) in Patients Aged ≥6 to <18 Years With Atopic Dermatitis (Eczema)
The primary objective of the study is to characterize the safety and pharmacokinetics (PK) of dupilumab in pediatric patients with moderate-to-severe atopic dermatitis (AD) (for adolescents ≥12 to <18 years of age) or severe AD…
- Trial name
- NCT02407756
- Testing
- Dupilumab
- Where
- 26 sites in Canada, Czechia and 4 more
- Volunteers
- 78 people
- Sponsor
- Regeneron Pharmaceuticals
Atopic Dermatitis
TRuE AD2 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis
The purpose of this study is to assess the efficacy of ruxolitinib cream in adolescents and adults with atopic dermatitis (AD).
- Trial name
- NCT03745651
- Testing
- Ruxolitinib cream, Vehicle cream
- Where
- 66 sites in United States, Bulgaria and 5 more
- Volunteers
- 618 people
- Sponsor
- Incyte Corporation
Atopic Dermatitis
Tapinarof for the Treatment of Atopic Dermatitis in Children and Adults
This is a double-blind, randomized, vehicle controlled Phase 3 study to evaluate the efficacy and safety of topical tapinarof cream, 1% compared to vehicle control cream in pediatric and adult subjects with atopic dermatitis.
- Trial name
- NCT05014568
- Testing
- tapinarof cream, 1%, Vehicle cream
- Where
- 67 sites in United States, Canada
- Volunteers
- 407 people
- Sponsor
- Organon and Co
Atopic Dermatitis
A Phase II Study in Adult Patients With Moderate to Severe Atopic Dermatitis
This proposed study is a randomized, double-blind, placebo-controlled, 3-arm parallel, multicenter phase II study, designed to explore the efficacy and safety of SHR0302 treatment for patients with moderate to severe atopic…
- Trial name
- NCT04162899
- Testing
- Drug: SHR0302
- Where
- 23 sites in China
- Volunteers
- 105 people
- Sponsor
- Reistone Biopharma Company Limited
Atopic Dermatitis
Tralokinumab in Combination With Topical Corticosteroids in Subjects With Severe Atopic Dermatitis - ECZTRA 7
Primary objective: To demonstrate that tralokinumab in combination with topical corticosteroids (TCS) is superior to placebo in combination with TCS in treating severe AD in subjects who are not adequately controlled with or have…
- Trial name
- ECZTRA 7 (NCT03761537)
- Testing
- Tralokinumab
- Where
- 74 sites in Belgium, Czechia and 5 more
- Volunteers
- 277 people
- Sponsor
- LEO Pharma
Atopic Dermatitis
Efficacy and Safety of MEDI3506 in Adult Subjects With Atopic Dermatitis
This is a research study to determine the efficacy and safety of investigational drug MEDI3506 for the treatment of adult subjects with Atopic Dermatitis.
- Trial name
- NCT04212169
- Testing
- MEDI3506
- Where
- 38 sites in United States, Australia and 4 more
- Volunteers
- 148 people
- Sponsor
- AstraZeneca
Atopic Dermatitis
A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab
The study will assess the safety and efficacy of lebrikizumab in adult and adolescent participants with moderate-to-severe atopic dermatitis (AD) previously treated with Dupilumab.
- Trial name
- ADapt (NCT05369403)
- Testing
- Lebrikizumab
- Where
- 37 sites in United States
- Volunteers
- 86 people
- Sponsor
- Eli Lilly and Company
Atopic Dermatitis
Tralokinumab in Combination With Topical Corticosteroids in Japanese Subjects With Moderate-to-severe Atopic Dermatitis
Primary objective: To evaluate the efficacy of tralokinumab in combination with topical corticosteroids (TCS) compared with placebo in combination with TCS in treating moderate-to-severe atopic dermatitis (AD).
- Trial name
- ECZTRA 8 (NCT04587453)
- Testing
- Tralokinumab, Topical corticosteroids (TCS)
- Where
- 25 sites in Japan
- Volunteers
- 106 people
- Sponsor
- LEO Pharma
Atopic Dermatitis
Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE)
This is a multicenter, randomized, double-blind, placebo-controlled study to be conducted in the United States in subjects with atopic dermatitis.
- Trial name
- NCT03568331
- Testing
- Tradipitant
- Where
- 70 sites in United States
- Volunteers
- 375 people
- Sponsor
- Vanda Pharmaceuticals
Atopic Dermatitis
A Phase II Study on Immunogenicity and Safety of MVA-BN® (IMVAMUNE™) Smallpox Vaccine in Subjects With Atopic Dermatitis
The purpose of this study is to compare the immunogenicity and safety of an investigational smallpox vaccine in subjects with atopic dermatitis to healthy volunteers.
- Trial name
- NCT00316602
- Testing
- IMVAMUNE
- Where
- 22 sites in United States, Mexico
- Volunteers
- 632 people, healthy volunteers welcome
- Sponsor
- Bavarian Nordic
Atopic Dermatitis
A Study of Baricitinib (LY3009104) in Adult Participants With Moderate to Severe Atopic Dermatitis
The purpose of this study is to evaluate the efficacy and safety of baricitinib in adult participants with moderate to severe atopic dermatitis.
- Trial name
- BREEZE-AD5 (NCT03435081)
- Testing
- Baricitinib
- Where
- 81 sites in United States, Canada and 1 more
- Volunteers
- 440 people
- Sponsor
- Eli Lilly and Company
Atopic Dermatitis
Efficacy and Safety Study of QAW039 in the Treatment of Patients With Moderate to Severe Atopic Dermatitis.
The purpose of this study is to determine whether QAW039 is safe and has beneficial effects in people who have moderate to severe atopic dermatitis (AD).
- Trial name
- NCT01785602
- Testing
- QAW039
- Where
- 18 sites in Australia, Austria and 6 more
- Volunteers
- 103 people
- Sponsor
- Novartis Pharmaceuticals